Regulatory requirements and benefits converting to Continued Process Verification
Magnus and Pharmadule at a glance

Director Regulatory Affairs, formerly scientific coordinator in the Inspections Sector, EMA
Responsible for Registration and Quality Management for both manufacturing and R&D-projects

• Pharmadule
  • Established in 1986
  • Acquired by Morimatsu Group in 2011
  • Has built >60 Pharmaceutical facilities
  • Big Pharma – Worldwide
  • 5 facilities in China
  • Full scope
    • Facilities
    • Regulatory Compliance
Agenda

- What is Process Validation
- Continued Process Verification
- Conclusions
Definition

Process Validation EU:
The documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its predetermined specifications and quality attributes.

Process Validation FDA
The collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product.
New approach to PV – Continuous/continual ...

Continuous Process Verification:
An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. (ICH Q8)

Continued Process Verification:
Documented evidence that the process remains in a state of control during commercial manufacture (FDA PV guide).

In the draft EU Annex 15 the word "on-going" has replaced "continued"
Traditional Process Verification via V-model

Quality Target Product Profile

Drives

Product specification

Verified by

End testing

Verify

Process Validation/Cleaning Validation

No/limited connection

User Requirement Specification

Functional Specification

Design Specification

Mechanical Fabrication

Fabrication of Hardware

Installation Qualification

Performance Qualification

Operational Qualification

Gap to be bridged by QbD

Three Batches Extended tests
A new approach to Process Validation & compliance

FDA PV - From Process Design throughout Continued Process Verification

References: FDA Process Validation: General Principles and Practices
EMA Guidelines for GMP Annex 15 (draft issued February 2014)
QbD and Continuous Process Verification

1. Quality Target Product Profile
   - DoE to determine criticality

2. Critical Quality Attributes
   - DoE to relate CPPs to CQAs

3. System design and Impact Assessment
   - DoE to replace by PAT
   - Real time release

4. Critical Process Parameters
   - DoE to verify co-variation
   - Parametric Release to remove an end-test

5. End testing CQA (HPLC, Elisa etc.)

6. In-line testing/monitoring CQA (NIR, conductivity etc.)

7. In-line Process Parametric Control (terminal sterilisation)

8. Product Specification
QbD and Continuous Process Verification

QbD

Hybrid Specifications may be the future
New EU variations regulation

2.8.2013

Official Journal of the European Union

B.II.g) Design Space and post approval change management protocol

<table>
<thead>
<tr>
<th>B.II.g.1 Introduction of a new design space or extension of an approved design space for the finished product, concerning:</th>
<th>Conditions to be fulfilled</th>
<th>Documentation to be supplied</th>
<th>Procedure type</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) One or more unit operations in the manufacturing process of the finished product including the resulting in-process controls and/or test procedures</td>
<td></td>
<td>1, 2, 3</td>
<td>II</td>
</tr>
<tr>
<td>b) Test procedures for excipients/intermediates and/or the finished product.</td>
<td></td>
<td>1, 2, 3</td>
<td>II</td>
</tr>
</tbody>
</table>

Documentation

1. Results from product and process development studies (including risk assessment and multivariate studies, as appropriate) demonstrating that a systematic mechanistic understanding of material attributes and process parameters to the critical quality attributes of the finished product has been achieved.

2. Description of the design space in tabular format, including the variables (material attributes and process parameters, as appropriate) and their proposed ranges.

3. Amendment of the relevant section(s) of the dossier (presented in the EU-CTD format or NTA volume 6B format for veterinary products, as appropriate).
In the future: Continued Process Verification

May be an option

– Under which conditions?

– How can it be achieved?
### Potential Opportunities to Enhance Science and Risk Based Regulatory Approaches *

*Note: This annex reflects potential opportunities to enhance regulatory approaches. The actual regulatory process will be determined by region.*

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Potential Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Comply with GMPs</td>
<td>Compliance – status quo</td>
</tr>
</tbody>
</table>
| 2. Demonstrate effective pharmaceutical quality system, including effective use of quality risk management principles (e.g., ICH Q9 and ICH Q10). | Opportunity to:  
  - increase use of risk based approaches for regulatory inspections.                                 |
| Demonstrate product and process understanding, including effective use of quality risk management principles (e.g., ICH Q8 and ICH Q9). | Opportunity to:  
  - facilitate science based pharmaceutical quality assessment;  
  - enable innovative approaches to process validation;  
  - establish real-time release mechanisms.                                                            |
| 4. Demonstrate effective pharmaceutical quality system and product and process understanding, including the use of quality risk management principles (e.g., ICH Q8, ICH Q9 and ICH Q10). | Opportunity to:  
  - increase use of risk based approaches for regulatory inspections;  
  - facilitate science based pharmaceutical quality assessment;  
  - optimise science and risk based post-approval change processes to maximise benefits from innovation and continual improvement;  
  - enable innovative approaches to process validation;  
  - establish real-time release mechanisms.                                                             |
Regular periodic or rolling quality reviews of all authorised medicinal products should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product, to highlight any trends and to identify product and process improvements.
Pharmaceutical Quality System (EU GMP)

§1.11
The manufacturer should evaluate the results of the review and an assessment made as to whether corrective and preventive action or any revalidation should be undertaken, under the **Pharmaceutical Quality System**
Continued Process Verification – During Life Cycle

1. Quality Target Product Profile → Critical Quality Attributes
2. System design and Impact Assessment → Critical Process Parameters
3. End testing (HP/LC, Elisa etc.)
4. In-line testing/monitoring (NIR, conductivity etc.)
5. In-line Process Parametric Control (terminal sterilisation)
6. Product Specification
7. Change Control
8. Continued Process Verification

Change outside approved process window:
- Regulatory action and revalidation needed

Regulatory impact:
- No impact:
  - Modify within approved process window
  - No regulatory action or revalidation needed

Data collection:
- Evaluate trends
- Trend reporting
- CC reporting
- Keep or change parameters/specs
- Operations:
  - Quality Assurance
  - Pre-validation Quality Risk Management
  - Regulatory filing
  - CTQ Module 3 / CMC
- Other Changes:
  - Raw material, equipment, utilities etc.
How to record Continued Compliance

• Quality System
• Change control (as mentioned before)
• Annual Product Quality Reviews
• Risk and science-based PV (but not necessarily QbD/Continuous Process Verification)
Conclusions

• Continued Process Verification
  – Can be done without variation registration
  – Requires Quality management system
    • Change control
    • Product quality reviews
    • Science and risk based process control

Implementing Continued probably makes more business sense than registering Continuous …
Thanks for your attention
Questions?

magnus.jahnsson@pharmadule.com
www.pharmadule.com